XNAS
NXTS
Market cap39kUSD
Oct 13, Last price
0.70USD
1D
-6.88%
1Q
-73.24%
IPO
-99.86%
Name
Nexentis Technologies Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shs. 5Y
97.02%
Rev. 5Y
%
Revenues
0
-100.00%
Net income
-4m
L-22.90%
CFO
-4m
L+11.38%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.
Key people
Independent Chairman of the Board · since 2021
David Palach
Chief Executive Officer · since 2023
Lital Barda
Chief Financial Officer · since 2023
Dan Sztybel
Chief Executive Officer of Save Foods Ltd. · since 2021
Shlomo Zakai
Financial Controller · since 2021
Asaf Itzhaik
Director · since 2023
Liat Sidi
Director · since 2023
Eliahou Arbib
Independent Director · since 2021
Israel Berenstein
Independent Director · since 2020
Udi Kalifi
Independent Director · since 2021
Ronen Rosenbloom
Independent Director · since 2020
Legal address
c/o VCORP SERVICES, LLC, 701 S. CARSON STREET, SUITE 200
Carson City, NV 89701
US
Carson City, NV 89701
US
Headquarters
5789 NW 7th Avenue
Miami, FL 33127
US
Miami, FL 33127
US
Previous name
N2OFF, INC.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||